ATE551358T1 - Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1 - Google Patents

Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1

Info

Publication number
ATE551358T1
ATE551358T1 AT05013817T AT05013817T ATE551358T1 AT E551358 T1 ATE551358 T1 AT E551358T1 AT 05013817 T AT05013817 T AT 05013817T AT 05013817 T AT05013817 T AT 05013817T AT E551358 T1 ATE551358 T1 AT E551358T1
Authority
AT
Austria
Prior art keywords
activity
xbp
methods
modulating
hepatocyte growth
Prior art date
Application number
AT05013817T
Other languages
English (en)
Inventor
Laurie H Glimcher
Andreas M Reimold
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE551358T1 publication Critical patent/ATE551358T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
AT05013817T 1999-12-30 2000-12-29 Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1 ATE551358T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17393199P 1999-12-30 1999-12-30

Publications (1)

Publication Number Publication Date
ATE551358T1 true ATE551358T1 (de) 2012-04-15

Family

ID=22634110

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00988444T ATE361934T1 (de) 1999-12-30 2000-12-29 Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1
AT05013817T ATE551358T1 (de) 1999-12-30 2000-12-29 Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00988444T ATE361934T1 (de) 1999-12-30 2000-12-29 Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1

Country Status (12)

Country Link
US (3) US6632608B2 (de)
EP (2) EP1254169B1 (de)
JP (1) JP2003518942A (de)
AT (2) ATE361934T1 (de)
AU (3) AU784883B2 (de)
CA (1) CA2396062C (de)
DE (1) DE60034817T2 (de)
DK (1) DK1254169T3 (de)
ES (1) ES2283340T3 (de)
MX (1) MXPA02006433A (de)
PT (1) PT1254169E (de)
WO (1) WO2001049717A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467759A4 (de) * 2002-01-30 2006-05-31 Brigham & Womens Hospital Zusammensetzungen und verfahren im zusammenhang mit tim-3, a th1-spezifischem zelloberflächenmolekül
US7666587B2 (en) * 2002-04-12 2010-02-23 New York University Method of screening test substances for treating or preventing a disease mediated by plasma cells
JP2006515154A (ja) * 2002-06-21 2006-05-25 セントカー・インコーポレーテツド モノクローナル抗体の作成方法
CA2496897C (en) * 2002-08-30 2012-01-31 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
WO2005078098A1 (en) * 2004-02-12 2005-08-25 The Walter And Eliza Hall Institute Of Medical Research Modified cells that co-express blimp1 and a reporter molecule and methods of using the same
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
WO2006031930A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Modulation of xbp-1 activity for treatment of metabolic disorders
SG166788A1 (en) * 2005-10-28 2010-12-29 Centocor Inc Use of b cell expansion agents in generating antibodies
AU2007221966A1 (en) * 2006-12-08 2008-06-26 Centenary Institute Of Cancer Medicine And Cell Biology Assay for response to proteasome inhibitors
US8227184B2 (en) * 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
EP2391372A4 (de) * 2009-01-30 2013-07-03 Bayer Healthcare Llc Verfahren zur behandlung von östrogenrezeptor-positivem tumor mittels hemmung des x-box-bindenden proteins 1
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2013134774A1 (en) 2012-03-09 2013-09-12 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
KR101864410B1 (ko) * 2016-01-21 2018-06-05 한국화학연구원 3차원 간세포 배양 유닛, 간독성 평가 시스템 및 이를 이용한 간독성 평가 방법
EP3630748B1 (de) 2017-06-01 2023-04-19 Cornell University Kleinmolekülige ire1-inhibitoren
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
WO2020011909A1 (en) * 2018-07-11 2020-01-16 Secarna Pharmaceuticals Gmbh & Co. Kg Nucleic acid polymers inhibiting the expression of xbp1

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
EP0391960B1 (de) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetische modifizierung von endothelialen zellen
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
CA2095153C (en) 1990-10-31 2007-01-09 Lori F. Rafield Genetic modification of endothelial cells
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
EP0580737B1 (de) 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0745121B1 (de) 1992-05-14 2007-06-20 Baylor College Of Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
ATE348175T1 (de) 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
EP0804561B1 (de) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulierte transkription von zielgerichteten genen und andere biologische ereignisse
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5650298A (en) 1993-06-14 1997-07-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP0721350A4 (de) 1993-07-30 1999-08-11 Univ Jefferson Intrazelluläre immunisierung
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US5840832A (en) * 1994-10-21 1998-11-24 The Johns Hopkins University Transcription factor regulating MHC expression, CDNA and genomic clones encoding same and retroviral expression constructs thereof
AU4483096A (en) 1995-01-31 1996-08-21 Novo Nordisk A/S A method of detecting biologically active substances
EP0857780A4 (de) * 1995-09-14 2001-12-05 Sumitomo Electric Industries Neue proteine die ausgezeichnet in leberkrebs expremiert werden, gene die diese proteine kodieren, antikörper gagegen und geeignete methoden
ATE259419T1 (de) * 1996-03-15 2004-02-15 Munin Corp Humanes cyr61, ein signalmolekül der extrazellulaeren matrix
NZ332897A (en) * 1996-04-23 2000-04-28 Harvard College Methods and compositions for modulating production of a T helper type 2 (Th2)-associated cytokine by regulating transcription factor activity in association with a Nuclear Factor of Activated T cells (NF-AT) protein
US5945307A (en) * 1998-01-26 1999-08-31 Millennium Pharmaceuticals, Inc. Isolated nucleic acid molecules encoding a G-protein coupled receptor showing homology to the 5HT family of receptors
CA2496897C (en) * 2002-08-30 2012-01-31 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity

Also Published As

Publication number Publication date
AU2006202243B2 (en) 2010-06-03
US20020059652A1 (en) 2002-05-16
US6632608B2 (en) 2003-10-14
DE60034817T2 (de) 2008-01-31
EP1626056A3 (de) 2006-05-03
ES2283340T3 (es) 2007-11-01
EP1626056B1 (de) 2012-03-28
CA2396062A1 (en) 2001-07-12
EP1626056A2 (de) 2006-02-15
AU2006202243A1 (en) 2006-06-22
MXPA02006433A (es) 2002-11-29
US7358415B2 (en) 2008-04-15
AU784883B2 (en) 2006-07-20
AU2010219305A1 (en) 2010-09-30
DK1254169T3 (da) 2007-08-06
DE60034817D1 (de) 2007-06-21
EP1254169A2 (de) 2002-11-06
ATE361934T1 (de) 2007-06-15
JP2003518942A (ja) 2003-06-17
WO2001049717A3 (en) 2001-12-06
AU2465301A (en) 2001-07-16
PT1254169E (pt) 2007-08-21
CA2396062C (en) 2009-11-17
US20080241114A1 (en) 2008-10-02
US20040110236A1 (en) 2004-06-10
WO2001049717A2 (en) 2001-07-12
EP1254169B1 (de) 2007-05-09

Similar Documents

Publication Publication Date Title
ATE551358T1 (de) Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1
CY1107689T1 (el) Μεθοδοι και μεσα ελεγχου της σιαλιωσης πρωτεινων που παραγονται απο κυτταρα θηλαστικων
RS49780B (sr) Primena derivata fumarne kiseline u transplantacionoj medicini
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
Davey et al. Spatial organization of embryonic stem cell responsiveness to autocrine gp130 ligands reveals an autoregulatory stem cell niche
DE69523771D1 (de) In vitro-modelle für cns-funktion und-dysfunktion
Eagleson et al. Region‐and age‐specific deficits in γ‐aminobutyric acidergic neuron development in the telencephalon of the uPAR–/–mouse
ATE359508T1 (de) Screening-verfahren unter verwendung von zebrafisch und der blut-hirn-schranke
BR0101294A (pt) Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores
Cameron et al. Activation of hypoxic response in human embryonic stem cell–derived embryoid bodies
Meng et al. Taste bud-derived BDNF is required to maintain normal amounts of innervation to adult taste buds
DE602007004143D1 (de) Verfahren zur Beurteilung der Lebensfähigkeit von Embryos
ATE466073T1 (de) Basalmedium zur kultivierung von es-zellen
Antonov et al. Current state-of-the-art and unresolved problems in using human induced pluripotent stem cell-derived dopamine neurons for parkinson’s disease drug development
Aoki et al. Cooperative and indispensable roles of endothelin 3 and KIT signalings in melanocyte development
ATE473273T1 (de) Angereicherte zellpopulationen des zentralen nervensystems
EP1687413B8 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
ATE505539T1 (de) Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren
Azcorra et al. Dopaminergic axons track somatic signaling in behaving mice
DE602004026445D1 (de) Verwendung von cardiotrophin zur modulation der stammzellenproliferation
ATE478156T1 (de) Verfahren zur identifizierung von modulatoren der eoxin-bildung
Lee et al. Delayed non-word repetition according to rehearsal conditions in 6-to 7-year-old children
BRPI0511365A (pt) processo de gerenciamento das renovações de subscrições para o estacionamento dos veìculos em uma área geográfica
DE69838278D1 (de) Verfahren zur diganose und feststellung der prädisposition von bipolaren gemütserkrankungen
Tähti et al. In vitro methods as a tool in neurotoxicity studies